Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Olanzapine Improves the Chemotherapy Tolerance of Advanced Gastric Cancer: a Prospective Randomized Controlled Phase II Clinical Study

NCT03575637 is registered in ClinicalTrials.gov with Peking University as lead sponsor.

NCT NCT03575637
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03575637 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Olanzapine Improves the Chemotherapy Tolerance of Advanced Gastric Cancer: a Prospective Randomized Controlled Phase II Clinical Study
Lead sponsor
Peking University
Phase
Phase 2
Overall status
Unknown status
Start date
July 31, 2018
Completion date
June 30, 2021
Enrollment
180 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer